- Trials with a EudraCT protocol (231)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
231 result(s) found for: Active immunization.
Displaying page 1 of 12.
EudraCT Number: 2007-001744-53 | Sponsor Protocol Number: PAI study | Start Date*: 2008-04-02 | ||||||||||||||||
Sponsor Name:University of Leipzig | ||||||||||||||||||
Full Title: Open, randomized study for evaluation of an active Hepatitis B vaccination(HBVAXPRO) in combination with a passive immunisation with Hepatitis B immunoglobulins (Hepatect) for subjects, who did not... | ||||||||||||||||||
Medical condition: Hepatitis B immunization | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005843-15 | Sponsor Protocol Number: Td9704-LT | Start Date*: 2016-01-26 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||
Full Title: One-, Three-, Five-, Eight- and Ten-Year Data on the Long- Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adults and Adolescents | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005845-30 | Sponsor Protocol Number: Td506-LT | Start Date*: 2016-01-26 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||
Full Title: One-, Three-, Five-, and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adults and Adolescents (11-64 ... | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005844-32 | Sponsor Protocol Number: Td9805-LT | Start Date*: 2016-01-26 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||
Full Title: One-, Three-, Five- and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adolescents 11–14 Years of Age | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003267-26 | Sponsor Protocol Number: BNT162-04 | Start Date*: 2020-09-02 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and immunogenicity of a prophylactic SARS-CoV-2 RNA vaccine (BNT162b3) against COVID-19 using different dosing regim... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004846-25 | Sponsor Protocol Number: Pfizer-Prevenar13-2015 | Start Date*: 2016-07-15 |
Sponsor Name:Maastricht University | ||
Full Title: Immunization against oxLDL in patients with lysosomal lipid diseases and associated metabolic disorders | ||
Medical condition: Familial hypercholesterolemia Niemann-Pick disease type B (NPB) Niemann-Pick disease type C (NPC) Partial lipodystrophy in children and adults | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000165-38 | Sponsor Protocol Number: V87P1E1 | Start Date*: 2007-06-22 | |||||||||||
Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. | |||||||||||||
Full Title: A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of FLUAD-H5N1 (Surface Antigen Adjuvanted with MF59C.1) Influenza Vaccine in Non-elderly Adult an... | |||||||||||||
Medical condition: Active immunoprofilaxis against potential pandemic influenza strain. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004288-37 | Sponsor Protocol Number: NOR-213 | Start Date*: 2017-03-15 | |||||||||||
Sponsor Name:Takeda Vaccines, Inc. | |||||||||||||
Full Title: A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects who have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine | |||||||||||||
Medical condition: Long-Term Immunogenicity Follow-up Trial of adult and Elderly Subjects who have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021068-13 | Sponsor Protocol Number: RPV03C | Start Date*: 2010-08-31 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur MSD S.N.C. | ||||||||||||||||||||||||||||||||||||||
Full Title: An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine ... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Repevax: Antibodies response to Diphtheria Toxoid ,Tetanus Toxoid, Pertussis Toxoid*, Filamentous Haemagglutinin, Pertactin, Fimbriae Types 2 and 3, Poliomyelitis Virus Type 1, Poliomyelitis Virus ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001038-36 | Sponsor Protocol Number: BNT162-01 | Start Date*: 2020-04-20 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in ... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005628-25 | Sponsor Protocol Number: Td540 | Start Date*: 2016-01-13 | |||||||||||||||||||||
Sponsor Name:Sanofi-Aventis K.K. | |||||||||||||||||||||||
Full Title: Immunogenicity and Safety of The tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (SP306) as a Booster in Japanese Adolescents | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003914-25 | Sponsor Protocol Number: Td527 | Start Date*: 2016-01-13 | |||||||||||||||||||||
Sponsor Name:SANOFI PASTEUR | |||||||||||||||||||||||
Full Title: Clinical Safety Study of the Tdap Combined Vaccine (ADACEL) as a Booster Dose in Healthy Adults and Children in China | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003941-24 | Sponsor Protocol Number: Td528 | Start Date*: 2016-01-13 | |||||||||||||||||||||
Sponsor Name:SANOFI PASTEUR SA | |||||||||||||||||||||||
Full Title: Immunogenicity and Safety of Sanofi Pasteur’s Tdap Combined Vaccine (ADACEL) as a Booster Dose, versus Local DT Vaccine in Healthy Children or versus Local Td Vaccine in Healthy Adolescents and Adu... | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021071-83 | Sponsor Protocol Number: FluvalAB-H-YL2010 | Start Date*: 2010-08-12 | |||||||||||
Sponsor Name:Omninvest Ltd. | |||||||||||||
Full Title: Tolerability and Immunogenicity Study of FluvalAB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/strain/0.5 mL) in Adults and Elderly Person | |||||||||||||
Medical condition: Immunization of healthy people against influenza virus infections. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002379-32 | Sponsor Protocol Number: FluvalAB-H-YL2012 | Start Date*: 2012-08-22 | |||||||||||
Sponsor Name:Omninvest Ltd. | |||||||||||||
Full Title: Tolerability and Immunogenicity Study of FLUVAL AB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 μgHA/strain/0.5 mL) in Adults and Elderly Persons | |||||||||||||
Medical condition: Immunization of healthy people against influenza virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002153-30 | Sponsor Protocol Number: FluvalAB-H-YL2013 | Start Date*: 2013-08-22 | |||||||||||
Sponsor Name:Omninvest Ltd. | |||||||||||||
Full Title: Tolerability and Immunogenicity Study of FLUVAL AB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 μgHA/strain/0.5 mL) for the Use in the Season 2013/2014 in Adults and Elderl... | |||||||||||||
Medical condition: Immunization of healthy people against influenza virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005842-69 | Sponsor Protocol Number: Td526 | Start Date*: 2016-01-26 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||
Full Title: Immune Responses in Adults to Revaccination with Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005590-20 | Sponsor Protocol Number: Td518 | Start Date*: 2016-01-13 | |||||||||||||||||||||
Sponsor Name:SANOFI PASTEUR | |||||||||||||||||||||||
Full Title: Safety Among Adolescents and Adults of Revaccination with Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 4 to 5 Years After a Previous Dose | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005627-84 | Sponsor Protocol Number: Td519 | Start Date*: 2016-01-13 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||||||||||||
Full Title: A pivotal open label, two-arm, multi-center trial to evaluate the safety and immunogenicity of a single dose of Adacel® vaccine in persons 10 to <11 years of age with the intent to extend the licen... | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005629-38 | Sponsor Protocol Number: Td551 | Start Date*: 2016-01-13 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||||||||||||
Full Title: Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
